|
KMID : 1037820150040010006
|
|
Journal of Pain and Autonomic Disorders
2015 Volume.4 No. 1 p.6 ~ p.12
|
|
|
Role of Botulinum Toxin Type A in Chronic Pain Management
|
|
이동국:Lee Dong-Kuck
저자없음:No authors listed
|
|
|
Abstract
|
|
|
|
Botulinum toxin (Botox) is a potent neurotoxin that is produced by the gram-positive, spore-forming, anaerobic bacterium, Clostridum botulinum. There are 7 known immunologically distinct serotypes of Botox: A, B, C1, D, E, F, and G. Among them, type A is most useful in clinical field. Since its introduction in the late 1970s, clinical application for Botox has continued to expand. Its analgesic effect has been used in clinical practice with some satisfactory results. Significant side effects are uncommon in Botox therapy, but contraindications to treatment with Botox include pregnancy, the concurrent use of aminoglycoside antibiotics, myasthenia gravis, Eaton-Lambert syndrome, or known sensitivity to the toxins. And follow-up should be arranged for 4-6 weeks following the injections, and more than one series of injections may be required to achieve maximal analgesic response. This review summarizes the clinical therapeutic effects of Botox in different types of chronic pain and its potential prospects.
|
|
|
KEYWORD
|
|
|
Botulinum toxin type A, Chronic pain
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|